Literature DB >> 1541707

Increased PIVKA-II concentrations in patients with cystic fibrosis.

M de Montalembert1, G Lenoir, A Saint-Raymond, J Rey, J J Lefrère.   

Abstract

Serum vitamin K concentrations and prothrombin induced by absence of vitamin K (PIVK-II) concentrations were assayed in 43 patients with cystic fibrosis. Twenty nine showed a normal PIVKA-II and vitamin K concentrations; 14 showed an increased PIVKA-II concentration, in one of whom serum vitamin K was decreased. Although their vitamin K concentrations were normal, some patients with cystic fibrosis still had an increased PIVKA-II. There was a significant correlation between PIVKA-II concentrations and the administration of antibiotics, a factor which has not previously been considered responsible for an increase in PIVKA-II.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1541707      PMCID: PMC495680          DOI: 10.1136/jcp.45.2.180

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  6 in total

1.  Plasma vitamin K1 concentrations in cystic fibrosis.

Authors:  I A Choonara; M J Winn; B K Park; J M Littlewood
Journal:  Arch Dis Child       Date:  1989-05       Impact factor: 3.791

2.  N-methyl-thio-tetrazole inhibition of the gamma carboxylation of glutamic acid: possible mechanism for antibiotic-associated hypoprothrombinaemia.

Authors:  J J Lipsky
Journal:  Lancet       Date:  1983-07-23       Impact factor: 79.321

3.  The effect of intravenous vitamin E and menadiol sodium diphosphate on vitamin K dependent clotting factors.

Authors:  L Helson
Journal:  Thromb Res       Date:  1984-07-01       Impact factor: 3.944

4.  Factor II (prothrombin) coagulant activity in immunoreactive protein: detection of vitamin K deficiency and liver disease in patients with cystic fibrosis.

Authors:  J J Corrigan; L M Taussig; R Beckerman; J S Wagener
Journal:  J Pediatr       Date:  1981-08       Impact factor: 4.406

5.  A new method to assay des-gamma-carboxyprothrombin. Results obtained in 75 cases of hepatocellular carcinoma.

Authors:  J P Soulier; D Gozin; J J Lefrere
Journal:  Gastroenterology       Date:  1986-11       Impact factor: 22.682

6.  Voltammetric behaviour of phylloquinone (vitamin K1) at a glassy-carbon electrode and determination of the vitamin in plasma using high-performance liquid chromatography with electrochemical detection.

Authors:  J P Hart; M J Shearer; P T McCarthy; S Rahim
Journal:  Analyst       Date:  1984-04       Impact factor: 4.616

  6 in total
  5 in total

Review 1.  The role of vitamins in cystic fibrosis.

Authors:  S B Carr; J McBratney
Journal:  J R Soc Med       Date:  2000       Impact factor: 5.344

2.  PIVKA-II concentrations in patients with cystic fibrosis.

Authors:  E A Cornelissen; A F van Lieburg; C G van Oostrom; L Monnens
Journal:  J Clin Pathol       Date:  1992-08       Impact factor: 3.411

Review 3.  Vitamin K in cystic fibrosis.

Authors:  S P Conway
Journal:  J R Soc Med       Date:  2004       Impact factor: 5.344

4.  Why bother to take vitamins?

Authors:  Alison Morton
Journal:  J R Soc Med       Date:  2011-07       Impact factor: 5.344

Review 5.  Vitamin K and the management of patients with cystic fibrosis.

Authors:  P R Durie
Journal:  CMAJ       Date:  1994-10-01       Impact factor: 8.262

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.